Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

athenahealth_More Disruption Please Conf 2016

athenahealth: More Disruption Please Conference 2016

athenahealth: More Disruption Please Conference 2016

Summary

Related Content

How Medicaid Cuts Could Reshape the Business of Health

AI Drug Discovery Tests the Limits of Patent Law

FDA Approves Lupin’s Pegfilgrastim Biosimilar, ARMLUPEG

BIOSECURE Act Included in Final Draft NDAA Compromise Text

Amgen, Hikma, and Gedeon Settle Denosumab BPCIA Case

Register Today: Webinar Series: An Overview of the Biosimilars Market in China, and Comparison with the US Market

USPTO Issues Revised Inventorship Guidance for AI-Assisted Inventions: Key Takeaways for AI/ML Innovators

European Commission Approves Alvotech’s and Teva’s Denosumab Biosimilars

Goodwin Advises Kymera Therapeutics in $690 Million Upsized Public Offering

Fondazione Telethon Announces Historic FDA Approval of Waskyra

Goodwin Advised Freenome on $330 Million deSPAC with Perceptive Capital Solutions at a Target $1.1 Billion Valuation

Van Lanschot Kempen N.V. and Swiss Life Banque Privée advised by Goodwin on the c. €105 million fundraising of Transgene

Goodwin Advised Royalty Pharma in $275 Million Royalty Funding Agreement with Denali Therapeutics

Nanobiotix Seals a Non-dilutive Royalty Financing Agreement for Up to $71 Million

State Drug Price Transparency Laws and Prescription Drug Affordability Boards – 2025 Year-End Review Webinar

Goodwin Guides Freenome in Over $200 Million Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

Life Sciences